| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-866 | |
| Phytochemical name or plant extracts | Viscosalactone B | |
| PMID | 14575818 | |
| Literature evidence | Therefore, incorporation of withanolides in the diet may prevent or decrease the growth of tumors in human. | |
| IUPAC name | (1S,2R,5S,6S,7R,9R,11S,12S,15R,16S)-5,6-dihydroxy-15-[(1S)-1-[(2R)-5-(hydroxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadecan-3-one | |
| Phytochemicals’ class or type of plant extracts | Withanolide | |
| Source of phytochemicals or plant Extracts | Withania somnifera | |
| Geographical availability | Afghanistan, Algeria, Angola, Assam, Bangladesh, Botswana, Burundi, Cameroon, Canary Is., Cape Provinces, Cape Verde, Chad, China North-Central, China South-Central, Cyprus, Djibouti, East Aegean Is., Egypt, Eritrea, Ethiopia, Free State, Greece, Gulf States, India, Iran, Kenya, Kriti, KwaZulu-Natal, Lebanon-Syria, Lesotho, Libya, Malawi, Mali, Mauritania, Morocco, Mozambique, Myanmar, Namibia, Niger, Nigeria, Northern Provinces, Oman, Pakistan, Palestine, Rwanda, Sardegna, Saudi Arabia, Sicilia, Sinai, Somalia, Spain, Sri Lanka, Sudan, Swaziland, Tanzania, Tunisia, Turkey, Uganda, West Himalaya, Yemen, Zambia, Zaïre, Zimbabwe | |
| Plant parts | Leaves | |
| Other cancers | Breast cancer, Lung cancer, Colon cancer, Brain cancer | |
| Target gene or protein | EGFR, HER2, estrogen and NF-κB receptors | |
| Gene or Protein evidence | We docked the phytochemicals and examined the binding affinities of ligands towards the EGFR, HER2, estrogen and NF-κB receptors. | |
| Target pathways | NA | |
| IC50 | Viscosalactone B (12) showed the 50% inhibition at concentrations ranging from 0.32 +/- 0.05 to 0.47 +/- 0.15 μg/mL | |
| Potency | W. somnifera leaves may be a potential source for the development of cancer therapeutics. | |
| Cell line/ mice model | MCF-7, NCI-H460, HCT-116, SF-268 | |
| Additional information | Viscosalactone B, as a novel LSD1 inhibitor, is a potential candidate that can be used for the treatment of prostate cancer in clinics. | |
| PubChem ID | 57403080 | |
| Additional PMIDs | 14575818 33525984 36692618 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:821709-1 | |
| Safety | NA |